跳至主要内容
临床试验/2023-506167-34-00
2023-506167-34-00撤回2 期

Improving inpatient GHB detoxification with baclofen: A proof of concept and dose-finding study.

Stichting Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2023年10月12日最近更新:

试验速览

阶段
2 期
状态
撤回
发起方
入组人数
28
试验地点
2
主要终点
The main study parameter is pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification in patients with GUD

研究概览

简要总结

To assess whether the baclofen add-on therapy reduces the need for pharmaceutical GHB during inpatient detoxification in patients with GUD

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • Diagnosed with GUD according to the DSM-V-TR criteria of substance use disorder
  • Indication for intramural GHB detoxification
  • GHB use >50ml/day
  • >18 years old

排除标准

  • Patients who has acute psychiatric co-morbidity that require immediate medical attention and interferes with the execution of the study, such as mania, delirium and psychosis
  • Physical contra-indications for baclofen
  • Body weight <55kg
  • Insufficient understanding of the Dutch language
  • GHB use >120ml/day
  • Comorbid benzodiazepine use >30mg diazepam equivalent per day
  • Use of antihypertensive drugs
  • Use of tricyclic antidepressant drugs

结局指标

主要结局

The main study parameter is pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification in patients with GUD

The main study parameter is pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification in patients with GUD

次要结局

未报告次要终点

研究者

发起方
Stichting Radboud University Medical Center
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Drs. Amber Wood

Scientific

Stichting Radboud University Medical Center

研究点 (2)

Loading locations...

相似试验